RECKLEEN is a lambda Red/CRISPR-Cas9 based single plasmid platform for enhanced genome editing in Klebsiella pneumoniae

TL;DR

RECKLEEN is a new tool for efficiently editing the genome of Klebsiella pneumoniae, a dangerous antibiotic-resistant bacteria, enabling faster and more precise genetic modifications.

Contribution

RECKLEEN introduces a single-plasmid CRISPR-lambda Red system for highly efficient and scalable genome editing in Klebsiella pneumoniae.

Findings

RECKLEEN achieves up to 99.998% killing efficiency using CRISPR-Cas9-based counterselection.

The system enables 100% efficient deletions, point mutations, and DNA integrations in counter-selected clones.

RECKLEEN supports multi-target deletions with up to 72% efficiency and works across multiple MDR Kp strains.

Abstract

Klebsiella pneumoniae (Kp) has evolved as a major public health threat due to its multidrug-resistance (MDR) and hypervirulence. Current Kp genome-editing tools are constrained by cumbersome workflows, low flexibility, and limited scalability. Here, we present the RECKLEEN system —Recombineering/CRISPR-based KLebsiella
Engineering for Efficient Nucleotide editing — as a single plasmid platform designed for precise genetic manipulation of Kp. RECKLEEN combines lambda Red recombineering with powerful CRISPR-Cas9-based targeted counterselection, achieving up to 99.998% killing efficiency. By implementing the near PAM-less SpG Cas9 variant in RECKLEEN, the compatible target sequence spectrum was significantly broadened. This approach enables deletions, point mutations, and DNA integrations, with efficiencies reaching 100% of the counter-selected clones. Simultaneous multi-target deletions were accomplished with up to 72% efficiency. To streamline the process, we developed a toolbox of eleven plasmids based on a modular cloning standard, enabling time- and resource-efficient assembly of editing constructs. This allows a 5-days workflow, from plasmid construction to the generation of strains with the desired genetic modification(s). The efficacy of RECKLEEN extends to various MDR Kp strains, such as ATCC 700721, ATCC BAA-1705, and ATCC 700603, demonstrating its broad applicability. RECKLEEN significantly enhances genome-editing capabilities for Kp, advancing research into its pathology and MDR mechanisms.

RECKLEEN, a CRISPR–recombineering platform, enables efficient, flexible, and scalable genome editing in multidrug-resistant Klebsiella pneumoniae, facilitating precise deletions, point mutations, and integrations across diverse clinical strains.

Figures